Acyclic Carbon Bonded Directly To Triazole Ring Nitrogen Is Multiple Bonded To An Additional Carbon Patents (Class 548/268.4)
  • Patent number: 8785481
    Abstract: The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: July 22, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Douglas C. Beshore, Vadim Dudkin, Robert M. Garbaccio, Adam W. Johnson, Scott D. Kuduk, Jason W. Skudlarek, Cheng Wang, Mark E. Fraley
  • Publication number: 20140155370
    Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
    Type: Application
    Filed: June 28, 2013
    Publication date: June 5, 2014
    Inventors: Sharon Shacham, Michael Kauffman, Vincent P. Sandanayaka, Sharon Shechter
  • Patent number: 8614217
    Abstract: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions wherein A represents a tetrazoyl group, Het represents a pyridyl group or a thiazolyl group and X represents various substituents.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: December 24, 2013
    Assignee: Bayer Cropscience AG
    Inventors: Christian Beier, Jürgen Benting, David Bernier, Isabelle Christian, Pierre-Yves Coqueron, Philippe Desbordes, Christophe Dubost, Pierre Genix, Daniela Portz, Ulrike Wachendorff-Neumann
  • Patent number: 8513230
    Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
    Type: Grant
    Filed: March 5, 2011
    Date of Patent: August 20, 2013
    Assignee: Karyopharm Therapeutics, Inc.
    Inventors: Sharon Shacham, Michael Kauffman, Vincent P. Sandanayaka, Sharon Shechter
  • Patent number: 8492388
    Abstract: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. wherein A represents a tetrazoyl group, Het represents a pyridyl group or a thiazolyl group and X represents various substituents.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: July 23, 2013
    Assignee: Bayer Cropscience AG
    Inventors: Christian Beier, Jürgen Benting, David Bernier, Isabelle Christian, Pierre-Yves Coqueron, Philippe Desbordes, Christophe Dubost, Pierre Genix, Daniela Portz, Ulrike Wachendorff-Neumann
  • Patent number: 8158642
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: April 17, 2012
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Christopher Michael Semko, Ying-zi Xu, Frank Stappenbeck, Jenifer Lea Smith, Kassandra Inez Rossiter, Juri Y. Fukuda, Andrei W. Konradi
  • Publication number: 20110275607
    Abstract: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
    Type: Application
    Filed: March 5, 2011
    Publication date: November 10, 2011
    Applicant: KARYOPHARM THERAPEUTICS, INC.
    Inventors: Sharon Shacham, Michael Kauffman, Vincent P. Sandanayaka, Sharon Shechter
  • Publication number: 20110172095
    Abstract: The present invention relates to compounds of the formula I in which the variables have the meanings defined in the claims and in the description.
    Type: Application
    Filed: September 3, 2009
    Publication date: July 14, 2011
    Applicant: BASF SE
    Inventors: Jochen Dietz, Thomas Grote, Wassilios Grammenos, Bernd Mueller, Jan Klaas Lohmann, Jens Renner, Sarah Ulmschneider, Marianna Vrettou
  • Publication number: 20110172096
    Abstract: The present invention relates to compounds of the formula I in which the variables have the meanings given in the claims and in the description.
    Type: Application
    Filed: September 3, 2009
    Publication date: July 14, 2011
    Applicant: BASF SE
    Inventors: Sarah Ulmschneider, Jochen Dietz, Jens Renner, Thomas Grote, Wassilios Grammenos, Bernd Mueller, Jan Klaas Lohmann, Marianna Vrettou
  • Publication number: 20100292472
    Abstract: The present invention can provide a novel medicament that is safe, cheap and effective for prophylaxis or therapy of apicomplexan infections, such as malaria and toxoplasmosis by applying a plant growth regulator selected from the group consisting of gibberellin inhibitors, cytokinins and ethylene inhibitors to the prophylactic or therapeutic treatment of such apicomplexan infections.
    Type: Application
    Filed: January 22, 2009
    Publication date: November 18, 2010
    Inventors: Tomoko Toyama, Kisaburo Nagamune, Toshihiro Horii, Kazuyuki Tanabe
  • Patent number: 7820663
    Abstract: The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of ?7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on ?7 nAChRs in a mammal by administering an effective amount of a compound of Formula I.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: October 26, 2010
    Assignee: The Regents of the University of California
    Inventors: Derk J. Hogenkamp, Timothy B. C. Johnstone, Kelvin W. Gee
  • Publication number: 20090137637
    Abstract: This invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R1, Q, W1, W2, R2a, L1, and R3, the pharmaceutical composition, the method of treating, and the therapeutic combination are as defined in the specification.
    Type: Application
    Filed: December 5, 2005
    Publication date: May 28, 2009
    Applicant: PFIZER INC.
    Inventors: Joe Nahra, Patrick Michael O'Brien
  • Publication number: 20070238765
    Abstract: The present invention provides a compound of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Y, Ar, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Application
    Filed: April 11, 2007
    Publication date: October 11, 2007
    Inventors: Xiao-Fa Lin, David Garrett Loughhead, Jason Manka, Counde O'Yang, Michael Soth, Dennis M. Yasuda
  • Publication number: 20040254373
    Abstract: The invention provides compounds of Formula I: 1
    Type: Application
    Filed: June 30, 2004
    Publication date: December 16, 2004
    Applicant: Pfizer Inc
    Inventors: David W. Piotrowski, Bruce N. Rogers, William W. McWhorter, Daniel Patrick Walker, Jeffrey W. Corbett, Vincent E. Groppi, Daniel G. Rudmann
  • Publication number: 20030216571
    Abstract: The present invention is to provide novel tricyclic compounds having leukotriene antagonistic action and represented by the formula: 1
    Type: Application
    Filed: July 31, 2002
    Publication date: November 20, 2003
    Inventors: Yoshiaki Kuroki, Hitoshi Ueno, Tetsushi Katsube, Tetsuo Kawaguchi, Eiji Okanari, Takashi Ikuta
  • Publication number: 20030125368
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: July 2, 2002
    Publication date: July 3, 2003
    Inventors: Subas M. Sakya, Andrei Shavnya, Bryson Rast
  • Publication number: 20030105105
    Abstract: The present application describes disubstituted pyrazolines and triazolines of formulae I and II: 1
    Type: Application
    Filed: June 26, 2002
    Publication date: June 5, 2003
    Inventor: Donald J.P. Pinto